JPRN-UMIN000043062已完成未知
HE4, yamamotoM - HE4, yamamotoM
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 21years-old 至 86years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Tumor-bearing and HD
研究者
相似试验
招募中
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.Type 1 Diabetes MellitusCTIS2023-510365-10-00Eli Lilly & Co.70
招募中
1 期
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants.HealthyMedDRA version: 21.1Level: PTClassification code: 10053643Term: Neurodegenerative disorder Class: 100000004852CTIS2023-504838-21-00Eli Lilly & Co.69
进行中（未招募）
1 期
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentProstatic NeoplasmsCTIS2023-503919-15-00Eli Lilly & Co.42
进行中（未招募）
1 期
未命名试验-MedDRA version: 20.0Level: LLTClassification code 10006173Term: Breast adenocarcinomaSystem Organ Class: 100000004864EUCTR2005-002385-11-ITF. HOFFMANN - LA ROCHE LTD.480
进行中（未招募）
1 期
FILOWM4-WaZaBi: Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemiaCTIS2023-505781-28-00French Innovative Leukemia Organization102